AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Every mission demonstrated the ability to adjust the crafts' inclination and apsis without issue. Gemini 5 demonstrated eight-day endurance, long enough for a round trip to the Moon. Gemini 7 demonstrated a fourteen-day endurance flight. Gemini 6A demonstrated rendezvous and station-keeping with Gemini 7 for three consecutive orbits at distances as close as 1 foot (0.30 m). Gemini 9A also achieved rendezvous with an Agena Target Vehicle (ATV). Rendezvous and docking with the ATV was achieved on Gemini 8, 10, 11, and 12. Gemini 11 achieved the first direct-ascent rendezvous with its Agena target on the first orbit. Extravehicular activity (EVA) was perfected through increasing practice on Gemini 4, 9A, 10, 11, and 12. On Gemini 12, Edwin "Buzz" Aldrin spent over five hours working comfortably during three (EVA) sessions, finally proving that humans could perform productive tasks outside their spacecraft. Gemini 10, 11, and 12 used the ATV's engine to make large changes in its orbit while docked. Gemini 11 used the Agena's rocket to achieve a crewed Earth orbit record apogee of 742 nautical miles (1,374 km). Gemini 8 experienced the first in-space mission abort on March 17, 1966, just after achieving the world's first docking, when a stuck or shorted thruster sent the craft into an uncontrolled spin. Command pilot Neil Armstrong was able to shut off the stuck thruster and stop the spin by using the re-entry control system. He and his crewmate David Scott landed and were recovered safely. Most of the novice pilots on the early missions would command the later missions.
=== Detection in serum and plasma === Magnesium status may be assessed by measuring serum and erythrocyte magnesium concentrations coupled with urinary and fecal magnesium content, but intravenous magnesium loading tests are more accurate and practical. A retention of 20% or more of the injected amount indicates deficiency. As of 2004, no biomarker has been established for magnesium. Magnesium concentrations in plasma or serum may be monitored for efficacy and safety in those receiving the drug therapeutically, to confirm the diagnosis in potential poisoning victims. The newborn children of mothers who received parenteral magnesium sulfate during labor may exhibit toxicity with normal serum magnesium levels.
ALN Magazine (ALN Mag.) ALN World (ALN World), no longer published Bioscience Technology (Biosci. Technol.) CED, formerly Communications, Engineering & Design Chem.Info Continuity Insights (Cont. Ins.), no longer an ABM brand Chromatography Techniques (Chromatogr. Tech.), no longer an ABM brand Controlled Environments Magazine (Control. Environ. Mag.) DFI News Digital Forensic Investigator (DFI News Digit. Forensic Investig.), no longer published Drug Discovery & Development (Drug Discov. Dev. also DDD Mag.) Electronic Component News (Electron. Compon. News also ECN) Food Manufacturing (Food Manuf.) Forensic Magazine (Forensic Mag.) Industrial Distribution (Ind. Distribution) Industrial Maintenance & Plant Operations (Ind. Maintenance Plant Oper.) Laboratory Design (Lab. Des.) Laboratory Equipment (Lab. Equip.) Manufacturing Business Technology (Manuf. Bus. Technol.) Manufacturing.net (Manuf. Net.) Medical Design Technology (Med. Des. Technol.) Pharmaceutical Processing (Pharm. Process.) Product Design & Development (Prod. Des. Dev.) R&D Magazine (R&D Mag.) Scientific Computing (Sci. Comput.) Surgical Products (Surg. Prod.) Wireless Design & Development (Wirel. Des. Dev.) Wireless Week (Wirel. Week)
Sources: en.wikipedia.org
Some raids were met with 100% of the fighters dispatched successfully engaging their targets, while German aircraft returned home over half the time never having seen the enemy. It is for this reason that Churchill credits Chain Home with winning the Battle.
Improved Benevolent and Protective Order of Elks Independent Benevolent and Protective Order of Moose Independent Order of Good Samaritans and Daughters of Samaria - Founded September 14, 1847, as a temperance order in New York City by I. W. B. Smith. It was an authorized branch of the white Grand United Order of Good Samaritans which had been founded that March. Had initiated over 400,000 members by 1897. It was described as having educational as well as mutual benefit aspects including sickness, death, disability, and old age benefits. In 1897 the Order had lodges in every US state and England. Its logo was a dove and olive branch enclosed in a triangle with the words Love, Purity, and Truth emblazoned on them. This symbolized perfection, equality, and the trinity. The Orders headquarters were in Washington, DC. Improved Order of the Shepherds and Daughters of Bethlehem - Founded in 1910 in Richmond, Virginia. Independent Order of Immaculates of the United States of America - Founded June 23, 1872, in Nashville, Tennessee, by W. A. Hadley. Evolved from Young Men's Immaculate Association but was different in that it was patterned after secret fraternal orders and that it admitted men and women. Had about 5,000 members in 1897. Headquartered in Nashville. Independent Order of Saint Luke - Based in Richmond, Virginia. Had 49,498 members at the end of 1921. Attempts to reach it in 1923 were unsuccessful.
== Etymology and pronunciation == The word hemostasis (, sometimes ) uses the combining forms hemo- and -stasis, Neo-Latin from Ancient Greek αἱμο- haimo- (similar to αἷμα haîma), meaning "blood", and στάσις stásis, meaning "stasis", yielding "motionlessness or stopping of blood".
RNA splicing is the process by which introns, regions of RNA that do not code for proteins, are removed from the pre-mRNA and the remaining exons connected to re-form a single continuous molecule. Exons are sections of mRNA which become "expressed" or translated into a protein. They are the coding portions of a mRNA molecule. Although most RNA splicing occurs after the complete synthesis and end-capping of the pre-mRNA, transcripts with many exons can be spliced co-transcriptionally. The splicing reaction is catalyzed by a large protein complex called the spliceosome assembled from proteins and small nuclear RNA molecules that recognize splice sites in the pre-mRNA sequence. Many pre-mRNAs, including those encoding antibodies, can be spliced in multiple ways to produce different mature mRNAs that encode different protein sequences. This process is known as alternative splicing, and allows production of a large variety of proteins from a limited amount of DNA.
Sources: en.wikipedia.org
Structural analogues of psilocybin (4-PO-DMT; O-phosphorylpsilocin) and psilocin (4-HO-DMT) include 4-hydroxytryptamine (4-HT), dimethyltryptamine (DMT), serotonin (5-hydroxytryptamine; 5-HT), bufotenin (5-HO-DMT), 6-hydroxy-DMT, 7-hydroxy-DMT, 4-AcO-DMT (psilacetin; O-acetylpsilocin), 4-PrO-DMT (O-propionylpsilocin), psilomethoxin (4-HO-5-MeO-DMT; 5-methoxypsilocin), 4-MeO-DMT (O-methylpsilocin; PSOM), 4-methyl-DMT, ethocybin (4-PO-DET), baeocystin (4-PO-NMT), aeruginascin (4-PO-TMT), and norbaeocystin (4-PO-T), among others.
Here, Cl is the total concentration of all polynucleotide chains belonging to a hypercycle Hl, C is the total concentration of polynucleotide chains belonging to all hypercycles, ql is the rate of growth, and φ is a dilution flux that guarantees that the total concentration is constant. According to the above model, in the initial phase, when several hypercycles exist, the selection of the hypercycle with the largest ql value takes place. When one hypercycle wins the selection and dominates the population, it is very difficult to replace it, even with a hypercycle with a much higher growth rate q.
I realized that for a long time I had been holding onto this whole dogma of nonracism almost like a religion ... But in the course of that debate I began to feel there was a lot lacking in the proponents of the nonracist idea ... they had this problem, you know, of superiority, and they tended to take us for granted and wanted us to accept things that were second-class. They could not see why we could not consider staying in that church, and I began to feel that our understanding of our own situation in this country was not coincidental with that of these liberal whites.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.